Pfizer has partnered with Syapse to use the San Francisco-based software company's data-sharing network and insights platform to advance the development of precision cancer treatments.
The companies' joint research will initially study molecular testing and therapy choices in precision oncology to better understand patient treatment journeys. To do so, Pfizer and Syapse will analyze real-world data from Syapse's network of health system partners, which includes Advocate Aurora Health, CommonSpirit Health, Henry Ford Health System and Providence St. Joseph Health, among others.
The research will then be used to improve patient care and accelerate the development and availability of new precision treatments from Pfizer, according to Syapse CEO Ken Tarkoff. "To realize the potential of precision medicine, all of the stakeholders in the healthcare ecosystem need to work together," he said.
More articles on health IT:
Children's National Health to apply AI to study ICU transitions
UCI Health to integrate mobile patient navigation app with Epic
ONC opens comment period for 2020 interoperability standards